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Small-bowel transplantation is now r.eady for clinical tri-
als. The surgical techniques and methods for immunosup-
pression and monitoring bowel status have been devel-
oped in animal models over the past 30 years. Several 
attempts at small-bowel transplantation in humans have 
already been reported. In the course of future trials, pa-
thologists will be involved in the monitoring of the post-
transplant course by mucosal biopsies and functional 
studies, including maltose and xylose absorption tests. 
The morphology of rejection has been studied in canine 
and rat models. Activated lymphocytes and plasma cells 
inflltrate the lamina propria and invade crypt epithelium, 
causing "cryptitis." Villous blunting ensues, reSUlting 
eventually in necrosis. Graft survival without immuno-
suppression is about 10 days. Under Cyclosporine immu-
nosuppression, a lymphoplasmacytic infiltrate has been 
noted around nerves and vessels in the submucosa. The 
overlying mucosa may be relatively normal. bnd~stage 
bowel is characterized by a contracted, scarred mass. 
Due to the large amount of lymphoid tissue in the al-
lograft, graft-versus-host disease is a significant problem 
in small-bowel transplantation. 
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After years of development in animal models, 
small-bowel transplantation is now approaching 
clinical application. Several attempts at small-
intestine transplantation in humans have been re-
ported (5,11,14), and the small bowel is included in 
multivisceral transplants (34,39). Surgical patholo-
gists will become increasingly involved in monitor-
ing the course of these patients, as they have in 
other transplant systems, because the morphologic 
evaluation of biopsy specimens is an important 
practical means for detecting rejection and distin-
guishing it from other modes of graft injury. 
The indications for performing small-bowel trans-
plantation have broadened as the techniques have 
become refined. More and more patients are being 
identified whQ may -benefit from this procedure. 
The initial small-bowel translllants in humans were 
performed 20 years ago for masSive intestInal in-
farction secondary to mesenteric vein thrombosis 
and as part of a pancreaticoduodenal-renal trans-
plant for diabetes (19). More recently, patients with 
Gardner's syndrome, inflammatory bowel disease, 
postsurgery or postradiation short-bowel syn-
drome, and congenital anomalies have been consid-
ered eligible. As in kidney, liver, bone marrow, and 
heart transplantation, patients with small-bowel 
transplants will eventually be followed in their com-
munities; therefore, pathologists in all types of 
practice will have to become familiar with the mor-
phologic appearances of small-bowel biopsy speci-
mens following transplantation. 
BACKGROUND 
Techniques for small-bowel transplantation have 
been developed over the past 30 years. The suc-
cessful canine small-bowel autografts with long-
term survivors performed by Lillehei et al. (17) 
yielded valuable data about the surgical techniques, 
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ischemia time, preservation methods, and rate of 
recovery of bowel function. These investigators 
subsequently noted that animals with small-bowel 
allografts given no immunosuppression died in 6--9 
days. The animals showed systemic signs of wast-
ing and enlarged mesenteric nodes but no cellular 
infiltrate in the graft. Lillehei et al. thereby 
recognized the potential for the development of 
graft-versus-host disease (GVHD), or "runting 
syndrome," after small-intestinal transplantation. If 
shorter bowel segments were transplanted and im-
munosuppression was added, the signs attributed'to 
GVH decreased, and the bowel segments were 
eventually rejected (25). 
During the 1960s and '70s, immunosuppression 
regimens, mainly Azathioprine and steroids, were 
tested to control GVH and rejection reactions 
(12,35). Mean survival was increased from 8 to 30 
days. With the introduction of Cyclosporine (CyA) 
in the mid 1980s, survivals beyond 8 months were 
noted in rodent studies (I5), and long-term survi-
vors (over 1 year) were reported in canine models 
(7). Preoperative graft irradiation alone was less 
successful in bidirectional or large animal models 
(3). Later, preoperative graft irradiation at higher 
doses together with Cy A produced long-term survi-
vors (38). 
The pioneering experiments of Monchik and Rus-
sell (23) showed that rejection and GVH reactions 
could be separated by using inbred strains of rat~ 
and their F1 hybrid offspring. Basically, transplant-
ing tissues from one parental strain into another 
constitutes a fully allogeneic "bidirectional" model 
in which either rejection or GVHD can occur. 
Transplantirw tissue from an Fl hybrid, which 
bears antigens from both parents, into a parental 
strain animal constitutes a semiallogeneic model in 
which only rejection can occur. Transplanting tis-
sue from a parent strain animal into an Fl hybrid 
offspring constitutes a semiallogeneic GVHD 
model. These have become the classic models for 
experimental studies in small-bowel transplanta-
tion. 
The introduction of functional tests for monitor-
ing rejection in the bowel was another advance. Al-
though morphologic assessment of small-bowel tis-
sue specimens is still the gold standard for recog-
nizing rejection in transplanted small intestine, this 
technique is not without flaws. Alternative means 
for monitoring graft function, such as maltose or 
xylose absorption studies, are being investigated. 
Although at present the results are variable and op-
erator-dependent, these tests appear to offer a sen-
sitive means to detect the mucosal damage that oc-
curs early in rejection. 
The ultimate refinement-namely, clinical tri-
als-has already begun. In the trials reported to 
date, monitoring of graft function has been by clin-
ical status and mucosal biopsy. However, there is 
now a need to develop sensitive and dependable 
laboratory techniques for monitoring the extended 
post-transplant course, to standardize the diagnos-
tic criteria for rejection and GVHD, and to identify 
criteria that will distinguish the immunologic reac-
tions from ischemic and infectious damage. 
TECHNIQUES 
The portion of bowel to be transplanted is re-
moved surgically, with its mesentery and vascular 
pedicle. The vessels and lumen of the bowel are 
flushed with cold Ringer's lactate or Eurocollin's 
solution. The maximum cold ischemia time, based 
on animal experiments (17), is 5 h. The bowel may 
be placed orthotopically, with end-to-end anasto-
mosis to the residual host bowel, or heterotopic ally , 
auxilliary to the native bowel, with exteriorized 
ends (Fig. 1). The latter placement, in which the 
bowel is vascularized but not nutritionally func-
tional, is a Thiry-Vella loop. The advantage of the 
Thiry-Vella loop is the easy access for absorption 
studies and biopsy; the disadvantage is that nutri-
tion must be maintained by the native bowel, and 
the functional ability of the Thiry-Vella loop is dif-
ficult to ascertain. The vascular anastomoses are 
superior mesenteric artery or aorta (with or without 
an aortic cuff) and donor superior mesenteric or 
FIG. 1. Diagram of a Thiry-Vella loop. 
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portal vein to recipient portal vein or inferior vena 
cava. The lymphatics and nerves are not repaired. 
Immunosuppression regimens include Azathio-
prine, Prednisone, CyA, and antilymphocyte serum 
in various combinations. Attempts have been made 
to ablate passenger lymphoid tissue by radiation 
(3,38) or surgical excision of mesenteric lymph 
nodes (6). Postoperatively, clinical signs such as 
weight loss, poor appetite, and diarrhea, as well as 
serum protein, triglyceride, and vitamin levels are 
determined as part of daily follow-up. Mucosal bi-
opsy and absorption studies may also be performed. 
SURVIVAL AND COMPUCATIONS 
Dogs undergoing intestinal autografts recover 
normal bowel function by 4 weeks (18,24). In the 
studies of Lillehei et al. (18), some animals were 
followed for 3 years. Histology and stool fat re-
turned to normal in a few weeks, and lymphatics 
regenerated between 2 and 6 weeks, as determined 
by methylene blue injection studies. 
Without immunosuppression, bowel allograft sur-
vival is about 6-12 days in all species studied 
(8,26,35). Azathioprine with or without Prednisone 
prolongs survival to an average of 21-42 days 
(13,35). CyA with or without Prednisone regimens, 
now more or less standard, have longer survivals; 
some studies have reported long-term survivors 
(8,15,17,26,38). 
In animals, causes of death in the immediate post-
transplant period are infarction of the graft due to 
arterial or venous thrombosis (26,28,38) and me-
chanical problems such as volvulus and intussus-
ception ~O4IOUIPUFK Acute rejection with graft necro-
sis, perforation, or peritonitis (7,15,28), or pneumo-
nia (26,38) is seen approximately 1 week 
posttransplantation. Causes of death in long-term 
survivors with CyA immunosuppression include in-
anition attributed to rejection and graft failure 
(7,8,26,28,38), pneumonia (26), and mechanical fac-
tors such as intestinal obstruction (26,28,38). Sys-
temic infection is rare, except for bacterial sepsis 
secondary to bowel perforation. In Williams's study 
of 27 dogs under Cy A immunosuppression after or-
thotopic transplant, fatal histoplasmosis occurred in 
two cases, and incidental giardiasis in five (38). Nei-
ther posttransplant lymphoproliferative disorder 
nor Cy A toxicity has been described in the animal 
models. 
Twelve cases of small-bowel transplant in hu-
mans have been reported. Survivals range from 0 to 
205 days (5,11,14,34,39). Most of the initial cases 
failed in the early posttransplant period because of 
technical reasons; one failed due to rejection, and 
another due to sepsis (14). The longest survivor (11) 
died with hepatorenal failure and Candida sepsis. 
The other two long-term survivors (34,39) died with 
posttransplant lymphoproliferative disorder at 4-6 
months posttransplant. Although the morphologic 
and physiologic effects of Cy A on small bowel are 
not known, Goulet et al. (11) suggest that CyA tox-
icity may have contributed to the renal insufficiency 
that was a major contributing factor in their pa-
tient's demise. 
BOWEL FUNCTION POSTIRANSPLANT 
Changes in bowel mucosa during the immediate 
posttransplant period were studied by Madara and 
Kirkman (20) using electrophysiologic and ultra-
structural techniques in a heterotopic rat model. 
They demonstrated that the earliest evidence of 
damage is in endothelial and crypt epithelial cells at 
3 days. Transepithelial resistance and spontaneous 
electrical potential difference decreased in both 
graft and host bowel at 3 days; host bowel recov-
ered, graft bowel did not. Crypt cell secretory func-
tion decreased by day 6; absorptive cell function 
was normal until day 9. The authors concluded that 
there is primary injury to endothelial and crypt cells 
after transplant and that absorptive cells are dam-
aged later, possibly due to ischemia. 
Most studies have focused on long-term bowel 
function, usually in animals under Cy A immuno-
suppression. Clinically, the animals exhibit diarrhea 
and a 30% weight loss, both of which are reversible 
over several weeks to mont lis (1,15,24,26;31). Se-
rum proteins and triglycerides remain normal 
(15,26). Absorption of various substances has been 
extensively investigated with the aim of developing 
a relatively noninvasive means for following mu-
cosal function posttransplant. Although assessment 
of the morphologic changes in tissue has been the 
gold standard for detecting rejection, mucosal biop-
sies are invasive and prone to sampling error, arti-
fact, and interference from inflammation around a 
stoma. These biopsies do not sample deeper layers 
of the wall where significant changes of rejection 
may be occurring while the overlying mucosa is rel-
atively normal, particularly in long-term survivors 
(1,9,22). 
Thus, absorption of tracer substances presents an 
attractive solution to these problems. The absorp-
tion of D-xylose, Cl4-glucose (24,26), and short-
and long-chain fatty acids (33) decreases as rejec-
tion develops. Unfortunately, Cyclosporine absorp-
tion also appears to be decreased during rejection 
(24); this decrease has obvious therapeutic implica-
tions. Absorption of maltose and lactose depends 
Am J Surg Palhol. Vol. 14. Supplement 1. 1990 
112 B. BANNER ET AL. 
on intact brush border enzymes in absorptive cells 
and appears to decrease before histologic evidence 
of rejection is present (2). This may be the most 
sensitive test for monitoring rejection. Long-term 
survivors with good nutritional status have normal 
maltose absorption (15). 
One caveat in all of these absorption studies is 
that bowel absorption of a number of substances 
has been shown to be dependent on an intact nerve 
and lymphatic supply. In the study of Ruiz et al., 
absorption of D-xylose dropped in nontransplanted 
bowels after interruption of nerves and lymphatics 
(28). Watson et al. (37) showed that the absorption 
of water and sodium, but not glucose, is reduced in 
transplanted bowel and denervated nontransplanted 
controls. These changes were not related to rejec-
tion or ischemia in the allografts. The implication 
was that the absorption of sodium and water is de-
pendent on an intact autonomic nerve supply. An-
other caveat in monitoring rejection by absorption 
studies is that the cellular targets in rejection have 
not been entirely elucidated. Madara and Kirk-
man's study implicated endothelial and crypt cells. 
In our own studies of small-bowel transplantation in 
a rat model, crypt damage seems to precede 
changes in the villous cell population. Thus, fimc-
tional tests such as maltose absorption, which re-
flect villous cell function, may not pick up the ear-
liest changes of rejection. In summary, the ideal 
functional test agent has yet to be developed. It 
need not be cell specific, but it should be sensitive 
to early mucosal damage and not to changes in-
duced by denervation or lymph stasis. 
Physiologic studies of motor function in canine 
heterotopic segmental jejunal transplants by 
Schi1l6r et al. (29) showed spasmodic uncoordinated 
electrical activity and vigorous peristalsis on inter-
ruption of blood supply, decreased motility during 
cold ischemia, and increased activity and tone on 
reperfusion. Except for this study, bowel motility 
after small-bowel transplant has not been investi-
gated. Motility disorders are a potential problem in 
long-term survivors. Muscle hypertrophy and poor 
motility were the major contributors to inanition in 
the study of canine long-term survivors after ortho-
topic transplant by Williams et al. (38). 
PATHOLOGY OF SMALL-BOWEL ALLOGRAFTS 
Ischemic Damage 
There are numerous studies of ischemia in small 
bowel after vascular ligation. Lillehei' s group (17) 
showed that canine bowel could tolerate 3 h of 
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clamping of the superior mesenteric artery; with hy-
pothermia the tolerance extended to 5 h. Similar 
studies in rat bowel (10,36) showed reversible dam-
age to villous epithelium progressing from tip to 
base with increasing degrees of ischemia. Damage 
occurred with as little as 15 min ischemia time and 
was irreversible with ischemia beyond a duration of 
2 h. Regeneration began as early as 12 h and was 
complete by 8 days. Lillehei's group also provided 
some of the initial data about methods to preserve 
bowel. With their techniques of perfusion and cold 
storage, mucosal damage was reduced (21). Holmes 
et al.'s classic description of the pathology of ca-
nine allografts notes congestion and necrosis of vil-
lous tips during the first 24 h (13). These changes 
were reversible by 3 days. The donor bowels had 
been prepared by vascular perfusion with cold 
Ringer's lactate. Rosemurgy and Schraut noted 
similar reversible changes in rat allografts (27). 
Vascular thrombosis has been a major complica-
tion and a cause of early postoperative death in 
small-intestinal transplantation, especially in large 
animal models (26,28,38). This complication has de-
creased with refinement of technique (J. W. 
Williams, unpublished data). 
Acute Cellular Rejection 
The morphologic features of acute cellular rejec-
tion have been studied in canine (1,4,9,13) and rat 
(27) models of small-intestinal transplanation. Cel-
lular rejection appears to begin at 3-6 days, with 
infIltration of the mucosa by activatedlYIDphocytes 
and plasma cells. There is corresponding mucosal 
edema, dilatation of lacteals, and blunting of villi. 
Inflammation increases and involves deeper layers 
of the wall. Eventually the entire bowel becomes 
necrotic, and the mucosa sloughs, usually by 10-12 
days. Bacterial superinfection may hasten this pro-
cess (13). In the case reported by Goulet et al. (11), 
there was an increase ofT helper cells, cells bearing 
IL2 receptors, and HLA-DR expression by crypt 
epithelial cells in mucosal biopsy specimens during 
rejection, Other than this report, however, there 
has not been a systematic study of the lymphocyte 
subpopulations inflltrating the small bowel during 
rejection. 
At the University of Pittsburgh, we have been 
using rat hybrid models to study the effects of var-
ious immunosuppressive regimens and immunode-
pletion techniques on rejection and GVH reactions. 
Histologic changes in the graft bowels in the semi-
allogeneic rejection model included necrosis, vil-
lous blunting, cryptitis, and inflammation of lamina 
propria first seen in and around the thin-walled vas-
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cular channels (A. Hoffman et aI., unpublished 
data) (Fig. 2). Larger vessels appeared spared ini-
tially. Host bowels from the semiallogeneic GVH 
group showed similar cryptitis and inflammation. 
These findings were identical to those described in 
GVH reactions in human bowel in bone marrow 
transplant patients by Snover et al. (32). Host bow-
els from the rejection group, donor bowels from the 
GVH group, and donor and host bowels from the 
syngeneic groups showed only occasional single-
cell necrosis without inflammatory response in 
crypts. Cryptitis and infiltration of the lamina pro-
pria by mononuclear cells appear to represent the 
morphologic expression of both cellular rejection 
and GVH reaction in the bowel. These findings are 
comparable to those in kidney and liver, where the 
pathogenesis of rejection involves infiltration by ac-
tivated lymphocytes and associated destruction of 
epithelial structures. 
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FIG. 2. Acute cellular rejection at 9 days in a semial-
logeneic (ACI-Lewis) F1 hybrid to Lewis rat model. 
Note villous blunting, single-cell necrosis in the crypts 
Ea~rowFI and inflammatory infiltrates in the lamina pro-
pna. 
Chronic Rejection 
Although the pathologic features of chronic rejec-
tion have not yet been established for bowel as they 
have in other organ systems, certain features that 
have been noted in long-term survivors of small-
bowel transplants are believed to represent a rejec-
tion reaction. In dogs with orthotopic allografts im-
munosuppressed with Cyclosporine (7) or Cyclo-
sporine plus pretransplant graft irradiation 0), a 
lymphoplasmacytic infiltrate around nerves, gan-
glia, and vessels in submucosa and muscle has been 
described (Fig. 3). In one study (1), this inflamma-
tory reaction persisted for months deep in the wall, 
while the overlying mucosa was normal. Eventu-
ally, most dogs in this study developed graft fibrosis 
and inanition. 
Millard et al. (22) described pathologic changes in 
mucosal biopsy specimens and full-thickness sec-
tions from heterotopic accessory small-bowel al-
lografts. Perivascular mononuclear cell infiltrates or 
fibrinoid necrosis were noted in and around submu-
cosal vessels. This finding was noted in full-
thickness sections of bowel but not in mucosal bi-
opsy specimens. The authors stress that mucosal 
biopsy specimens are not a reliable way to monitor 
~hronic rejection, because they do not show signif-
Icant changes occurring in the submucosa. 
Fujiwara et al. (9) also described fibrinoid necro-
sis and inflammation in small submucosal arteries in 
21.4% of the dogs with orthotopic small-bowel 
transplants from both" the treated and nontreated 
groups. Thus, it seems thathistopatbologic changes 
occur throughout the wall after small-bowel trans-
plantation. These histopathologic changes are not 
those usually seen with injury due to ischemia or 
infection; they appear to represent the pathologic 
process of rejection. 
Some studies (1,9) suggest that significant mor-
phologic changes may occur without functional ab-
normalities for a while, but eventually there is a 
slow progression to an end stage of fibrosis of the 
graft, followed by death of the animal due to inani-
tion. One may speculate that inflammation or vas-
cular compromise deep in the wall, particularly in 
muscle, contributes to the motility problems noted 
frequently in long-term survivors (38). These prob-
lems may parallel the functional changes seen in 
~ther organs with graft failure due to chronic rejec-
hon. 
GRAFr-VERSUS-HOST DISEASE 
Because of the large volume of lymphoid tissue 
associated with the bowel, GVHD presents a major 
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(b) 
... . 
FIG. 3. Chronic cellular rejection at 3 months in a canine allograft immunosup-
pressed by Cyclosporine and pretransplant graft irradiation. (a) Low power showing 
concentration of inflammation in submucosa, with intact ml!cosa. (b) Higher power 
showing Iymphoplasmacytic infiltrate in nerves and vessels in submuCO!?I;l. _ 
problem in small-bowel transplantation. There may 
be species differences in susceptibility to GYHD, 
and the potential for bowel allografts to mount such 
a response in humans is currently unknown. Also, 
development of GYHD may relate to whether prox-
imal or distal bowel is transplanted and to the 
amount of bowel (and lymphoid tissue) trans-
planted. 
Lillehei et ai. (16,18) were the first to recognize 
that GYHD could cause morbidity and death after 
small-bowel transplantation, although GYHD was 
not known as such at that time. Their dogs with 
homografts died within the time frame expected for 
rejection, but the grafts showed no evidence of re-
jection at autopsy, leading to the conclusion that the 
homograft was, in some manner, rejecting the host. 
Monchik and Russell (23) offered the first descrip-
tions of GYHD in their semiallogeneic models. Two 
notable current studies are those of Schraut et al. 
Am J Surg Pathol, Vol. 14, Supplement 1, 1990 
(30) and Deitz et al. (6). Schraut et al. described 
GYHD after orthotopic and heterotopic transplan-
tation in a Lewis to (Lewis x Brown Norway) Fl 
semiallogeneic (GYH) hybrid rat model. Clinically, 
dermatitis and weight loss appeared over days 9-11, 
and death resulted by day 14. Histologically, host 
bowel displayed inflammation while graft bowel 
was normal. Lymphoid tissue displayed progressive 
lymphocyte depletion after day 5. 
Deitz et ai. studied the effects of various types of 
immunodepletion on reducing GYHD in Brown 
Norway to (Lewis x Brown Norway) Fl accessory 
heterotopic small-bowel transplants in the rat. An-
imals treated with Cyclosporine, irradiation, or 
mesenteric lymphadenectomy lived 12{}-150 days 
and had no GYHD or in vitro T-lymphocytotoxic 
antihost activity. It is of note that GVHD has not 
been a significant complication in the human cases 
reported thus far. 
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SUMMARY 
Small-bowel transplantation has reached the level 
of clinical application; the indications have been de-
fined, and the techniques have been developed. The 
immunosuppression regimens are being formulated. 
A major area of current investigation is to find ac-
curate, yet relatively noninvasive ways to monitor 
the posttransplant course and to detect rejection 
and GVHD. At present, musocal biopsies and mal-
tose absorption tests are preferred. Because infll-
tration of the lamina propria by activated lympho-
cytes and cryptitis are the early manifestations of 
acute cellular rejection, biopsies are useful initially. 
However, in long-term survivors under Cy A immu-
nosuppression, the mucosa may appear normal, and 
the only manifestation of rejection may be a lym-
phoplasmacytic infiltrate in the submucosa. The 
next steps in understanding the pathogenesis of re-
jection in small-bowel allografts will include (a) the 
immunophenotypic characterization of the infiltrat-
ing cells as to donor or host origin, (b) the better 
delineation of the morphologic changes due to drug 
toxicity and perfusion injury, and (c) correlation of 
histology with absorptive function over time to de-
termine the sensitivity of noninvasive functional 
tests and their ability to predict long-term bowel 
function. 0 
REFERENCES 
1. Banner B, Dean P, Williams J. Morphologic features of re-
jection in long-surviving canine small bowel transplants. 
Transplantation 1988;46:665-9. 
2. Billiar TR, Garberoglio C, Schraut WHo Maltose absorption 
as an indicator of small-intestinal allograft rejection. J Surg 
Res 1984;37:75-82. 
3. Cohen Z, MacGregor AB, Moore KTH, Falk RE, Langer B, 
Cullen JB. Canine small bowel transplantation. Arch Surg 
1976;111 :248-53. 
4. Cohen Z, Nordgren S, Lossing A, Cullen J. Craddock G, 
Langer B. Morphologic studies of intestinal allograft rejec-
tion. Immunosuppression with Cyclosporine. Dis Colon 
Rectum 1984;27:228-34. 
5. Cohen Z, Silverman RE, Wassef R, et al. Small intestinal 
transplantation using Cyclosporine. Transplantation 1986; 
42:613-21. 
6. Deitz E, Ulrichs K, Schack T, et aI. Graft-versus-host reac-
tion in small bowel transplantation and possibilities for its 
circumvention. Am J Surg 1986;51:379-86. 
7. Diliz-Perez HS, McClure J, Bedetti C, et aI. Successful small 
bowel allotransplantation in dogs with cyclosporine and 
prednisone. Transplantation 1984;37: 126-9. 
8. Fijuwara H. Grogan JB, Raju S. Total orthotopic small 
bowel transplantation with cyclosporine. Transplantation 
1987;44:469-78. 
9. Fijuwara H, Raju S, Grogan JB, Lewin JR, Johnson WW. 
Total orthotopic small bowel allotransplantation in the dog. 
Transplantation 1987;44:747-53. 
10. Gabbert H, Wagner R, Aust P, Hohn P. Ishchemia and post-
ischemic regeneration of the small intestinal mucosa. An 
enzyme-histochemical investigation. Acta Histochem 1978; 
63:197-213. 
11. Goulet OJ, Revillon Y, Cerf-Bensussan N, et al. Small in-
testinal transplantation in a child using cyclosporine. Trans-
plant Proc 1988;20:288-96. 
12. Hardy MA, Quint J, State D. Effect of antilymphocyte se-
rum and other immunosuppressive agents on canine jejunal 
allografts. Ann Surg 1970;171:51-60. 
13. Holmes IT, Klein MS, Winawer SI, Fortner JG. Morpho-
logical studies of rejection in canine jejunal allografts. Gas-
troenterology 1971 ;61 :693-706. 
14. Kirkman RL. Small bowel transplantation. Transplantation 
1984;37:429-33. 
15. Lee KKW, Schraut WHo Structure and function of ortho-
topic small bowel allografts in rats treated with cyclospo-
rine. Am J Surg 1986;151:55-60. 
16. Lillehei RC, Goott B, Miller FA. Homografts of the small 
bowel. Surg Forum 1959;10:197-201. 
17. Lillehei RC, Goott B, Miller FA. The physiological response 
of the small bowel of the dog to ischemia including pro-
longed in vitro preservation of the bowel with successful 
replacement and survival. Ann Surg 19R9;1RM:R4~K 
18. Lillehei RC, Goldberg S, Goott B, Longerbeam JK. The 
present status of intestinal transplantation. Am J Surg 
1963;105:58-72. 
19. Lillehei RC, Idezuki Y, Feemster JA, et al. Transplantation 
of stomach, intestine, and pancreas: experimental and clin-
ical observations. Surgery 1%7;62:721-41. 
20. Madara JL, Kirkman RL. Structural and functional evolu-
tion of jejunal allograft rejection in rats and the ameliorating 
effects of cyclosporine therapy. J Clin Invest 1985;75:502-
12. 
21. Manax WG, Bloch JH, EyaI Z, Lillehei Re. Experimental 
preservation of the small bowel. Am J Surg 1965;109:26-31. 
22. Millard PR, Dennison A, Hughes DA, Collin J, Morris PJ. 
Morphology of intestinal allograft rejection and the inade-
quacy of mucosal biopsy in its recognition. Br J Exp Pat hoi 
1986;67:687-98. 
23. Monchik GJ, Russell ps. Transplantation of small bowel in 
the rat: technical and immunologicat consideratio9s. Sur-
gery 1971 ;70:693-702. 
24. Nordgren S, Cohen A, Mackenzie R, Finkelstein D, Green-
berg GR, Langer B. Functional monitors of rejection in 
small intestinal transplants. Am J Surg 1984;147:152-8. 
25. Preston FW, MacaIalad F, Wachowdki TJ, Randolph DA, 
Apostol JV. Survival of homografts of the intestine with and 
without immunosuppression. Surgery 1966;60:1203-10. 
26. Reznick RK, Craddock GN, Langer B, Gilas T, Cullen JB. 
Structure and function of small bowel allografts in the dog; 
immunosuppression with CycIosporin A. Can J Surg 
1982;25:51-5. 
27. Rosemurgy AS, Schraut WH. Small bowel allografts. Se-
quence of histologic changes in acute and chronic rejection. 
Am J Surg 1986;151:470-5. 
28. Ruiz JO, Uchida H, Schultz LS, Lillehei RC. Problems in 
absorption and immunosuppression after entire intestinal al-
lotransplantation. Am J Surg 1972;123:297-303. 
29. Schiller WR, Suriyapa C, Mutchler JHW, Gohara SF, 
Anderson MC. Motility changes associated with canine in-
testinal allografting. J Surg Res 1973;15:379-84. 
30. Schraut WH, Lee KKW, Dawson PJ, Hurst RD. Graft-
versus-host disease induced by small bowel allografts. Clin-
ical course and pathology. Transplantation 1986;41:286-90. 
31. Schraut WH, Lee KKW, Sitrin M. Recipient growth and 
nutritional status following transplantation of segmental 
small-bowel allografts. J Surg Res 1987;43: 1-9. 
32. Snover DC, Weisdorf SA, Vercellotti GM, Rank B, Hutton 
Am J Surg Pathal. Vol. 14. Supplement 1. 1990 
116 B. BANNER ET AL. 
S, McGlave P. A histopathologic study of gastric and small 
intestinal Graft versus Host disease following allogeneic 
bone marrow transplantation. Hum PathoI1985;16:387-92. 
33. Stamford wp, Hardy MA. Fatty acid absorption in jejunal 
autograft and allograft. Surgery 1974;75:496-502. 
34. Starzl TE, Rowe MI, Todo S. et al. Transplantation of mul-
tiple abdominal viscera. JAm Med Assoc 1989;261:1449-57. 
35. Taylor RMR, Watson JW, Walker FC, Watson AJ. Prolon-
gation of survival of jejunal homograft in dogs treated with 
azathioprine (!muran). Br J Surg 1966;53:134-8. 
36. Wagner R, Gabbert H, Hohn P. Ischemia and post-ischemic 
regeneration of the small intestinal mucosa. A light micro-
Am J Surg Pathol, Vol. 14, Supplement I. 1990 
scopic and autoradiographic study. Virchows Arch [B) 
1979;31 :259-76. 
37. Watson AIM, Lear PA, Montgomery A, et aI. Water, elec-
trolyte, glucose, and glycine absorption in rat small intesti. 
nal transplants. Gastroenterology 19UU;94:US~9K 
38. Williams JW, McClellan T, Peters TG, et aI. Effect of pre-
transplant graft irradiation on canine intestinal transplanta-
tion. Surg Gynecol Obstet 1988;167:197-204. 
39. Williams JW, Sankary HN, Foster PF, Lowe J, Goldman 
GM. Splanchnic transplantation. An approach to the infant 
dependent on parenteral nutrition who develops irreversible 
liver disease. JAm Med Assoc 1989;261:1458-62. 
